These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 7481860

  • 1. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C.
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [Abstract] [Full Text] [Related]

  • 3. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD, Minnie Pearl Cancer Research Network.
    Cancer; 2003 Nov 15; 98(10):2192-8. PubMed ID: 14601089
    [Abstract] [Full Text] [Related]

  • 7. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F.
    Cancer; 2001 Jun 01; 91(11):2039-45. PubMed ID: 11391583
    [Abstract] [Full Text] [Related]

  • 8. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
    Keren-Rosenberg S, Muggia FM.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 3):S26-9. PubMed ID: 9071337
    [Abstract] [Full Text] [Related]

  • 9. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 10. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M.
    Clin Cancer Res; 2003 Jun 15; 9(6):2098-107. PubMed ID: 12796374
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C.
    J Clin Oncol; 1997 Sep 15; 15(9):3156-63. PubMed ID: 9294479
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.
    Cancer; 2004 Nov 01; 101(9):2034-41. PubMed ID: 15455357
    [Abstract] [Full Text] [Related]

  • 13. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I, Destefanis P, Addeo A, Galetto A, Cucchiarale G, Munoz F, Zitella A, Ferrando U, Fontana D, Ricardi U, Tizzani A, Bertetto O.
    Am J Clin Oncol; 2007 Jun 01; 30(3):234-8. PubMed ID: 17551298
    [Abstract] [Full Text] [Related]

  • 14. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
    Vaughn DJ, Brown AW, Harker WG, Huh S, Miller L, Rinaldi D, Kabbinavar F.
    Cancer; 2004 Feb 15; 100(4):746-50. PubMed ID: 14770430
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA, Ilson DH, Kelsen DP.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [Abstract] [Full Text] [Related]

  • 16. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 17. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
    DiPaola RS, Aisner J.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 2):112-6. PubMed ID: 10190792
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel in the treatment of hormone-refractory prostate cancer.
    Smith DC, Pienta KJ.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 2):109-11. PubMed ID: 10190791
    [Abstract] [Full Text] [Related]

  • 19. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC.
    Clin Genitourin Cancer; 2007 Jun 01; 5(5):318-22. PubMed ID: 17645828
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.